Cidara Therapeutics, a preclinical biotech developing novel therapies for fungal infections, raised $77 million by offering 4.8 million shares at $16, the high end of the range of $14 to $16. Cidara Therapeutics plans to list on the NASDAQ under the symbol CDTX. Cidara Therapeutics initially filed confidentially on 2/4/2015. Jefferies & Co. and Leerink Partners acted as lead managers on the deal.
